研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

肿瘤治疗中刺激响应型纳米异质结构的最新进展。

Recent advances in stimuli-responsive nano-heterojunctions for tumor therapy.

发表日期:2023 Apr 07
作者: Jing Ping, Jun Du, Ruizhuo Ouyang, Yuqing Miao, Yuhao Li
来源: BIOMEDICINE & PHARMACOTHERAPY

摘要:

基于纳米触媒的刺激响应型催化疗法因其出色和独特的特性,受到生物医药领域肿瘤治疗的广泛关注。然而,复杂的肿瘤微环境条件和触媒中快速的电荷复合限制了催化疗法的有效性和进一步开发。为了提高催化性能,构建了有效的异质结纳米材料以解决这些问题。具体而言,一方面,通过异质结构调整材料的带隙,以促进外源刺激下的电荷分离效率,进一步提高催化能力。另一方面,异质结构的构建不仅可以保留原始触媒的功能,还可以实现显著增强的协同治疗能力。本文综述了近年来在X射线、可见近红外光和超声激发下的刺激响应型异质结纳米材料的构建和功能,并进一步介绍了它们在癌症治疗中的应用。希望总结刺激响应型异质结纳米材料的应用能帮助研究人员推进纳米材料在癌症治疗中的发展。版权所有©2023 Elsevier B.V.
Stimuli-responsive catalytic therapy based on nano-catalysts has attracted much attention in the field of biomedicine for tumor therapy, due to its excellent and unique properties. However, the complex tumor microenvironment conditions and the rapid charge recombination in the catalyst limit catalytic therapy's effectiveness and further development. Effective heterojunction nanomaterials are constructed to address these problems to improve catalytic performance. Specifically, on the one hand, the band gap of the material is adjusted through the heterojunction structure to promote the charge separation efficiency under exogenous stimulation and further improve the catalytic capacity. On the other hand, the construction of a heterojunction structure can not only preserve the function of the original catalyst but also achieve significantly enhanced synergistic therapy ability. This review summarized the construction and functions of stimuli-responsive heterojunction nanomaterials under the excitation of X-rays, visible-near infrared light, and ultrasound in recent years, and further introduces their application in cancer therapy. Hopefully, the summary of stimuli-responsive heterojunction nanomaterials' applications will help researchers promote the development of nanomaterials in cancer therapy.Copyright © 2023 Elsevier B.V. All rights reserved.